GMMG Multiple Myeloma Registry
This study, called the GMMG Multiple Myeloma Registry, is designed to keep track of the long-term health of people in Germany with multiple myeloma. These individuals have previously participated in treatment studies run by a group called the German-Speaking Myeloma Multicenter Group (GMMG). The main goal is to collect information on how patients do over many years, looking at things like how long they live, how long they stay free from their cancer getting worse, and how their treatment plans change over time. By combining this new information with data from previous studies, researchers hope to get a clearer picture of the best ways to treat multiple myeloma and improve patients' lives. This is an 'observational' study, meaning patients receive their usual care, and researchers simply gather information without giving new treatments as part of this specific registry.
Auf einen Blick
Worum geht es in dieser Studie?
This registry is a long-term study that collects important health information from people in Germany who have multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow. The people included in this registry have already taken part in previous treatment studies led by a group called the German-Speaking Myeloma Multicenter Group (GMMG).
The main idea behind this registry is to continue gathering information about these patients over many years, even after their original treatment studies have finished. This helps doctors and researchers understand the long-term effects of different treatments. They want to see how long people live overall, how long they stay well without their cancer getting worse, and what happens to their health over a long period. By combining this new, ongoing information with what they already know from the previous studies, they can learn a great deal about the best ways to manage multiple myeloma.
This kind of study is really important because it helps improve future care for others with multiple myeloma. It provides valuable insights into how treatments work in the real world and over time, allowing doctors to make more informed decisions and develop better treatment strategies. It started in late 2022 and involves many cancer centers across Germany.
Wichtige Erkenntnisse
- This is a registry for people with multiple myeloma who were in past GMMG studies.
- It collects long-term health information to understand treatment effects over many years.
- No new treatments are given; you'll receive your usual care.
- Information is collected every 6-12 months.
- Your participation helps improve future care for multiple myeloma patients.
- You can withdraw from the registry at any time.
Wer könnte berechtigt sein?
To be part of this registry, you must have previously participated in a treatment study run by the German-Speaking Myeloma Multicenter Group (GMMG). This means you would have already been treated for multiple myeloma as part of one of their specific research trials.
People who had a condition called organ amyloidosis at the time they were diagnosed with multiple myeloma would not be able to join this registry. Organ amyloidosis is when abnormal proteins build up in organs and can cause health problems.
This registry is open to adults aged 18 and older, and it includes both men and women.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Have I been diagnosed with multiple myeloma?
- Did I previously take part in a treatment study from the GMMG group?
- Bin ich 18 Jahre oder älter?
- Did I NOT have organ amyloidosis when I was first diagnosed with multiple myeloma?
Was beinhaltet die Teilnahme?
If you are eligible and agree to take part, your contribution to this registry will mainly involve allowing researchers to continue gathering information about your health. You will continue to receive your standard medical care from your own doctors, as you normally would. This study does not involve new treatments or medical procedures.
Researchers will collect information every six months until your cancer progresses (gets worse). After that, they will collect information once a year. This data includes details about your treatment, your current health, and how you are doing. The information collected will be kept private and stored in a secure electronic system. You can choose to stop participating at any time.
Potenzielle Risiken und Vorteile
Locations (35)
- HELIOS Klinikum, Klinik für Hämatologie, Onkologie und ImmunologieVerifizierte PostleitzahlBerlin, Deutschland· Rekrutierung
- Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie)Verifizierte PostleitzahlBerlin, Deutschland· Rekrutierung
- Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und PalliativmedizinVerifizierte PostleitzahlBielefeld, Germany· Rekrutierung
- Medizinische Universitätsklinik, KnappschaftskrankenhausVerifizierte PostleitzahlBochum, Germany· Rekrutierung
- Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und RheumatologieVerifizierte PostleitzahlBonn, Deutschland· Rekrutierung
- Klinikum Chemnitz GmbH, Innere Medizin IIIVerifizierte PostleitzahlChemnitz, Germany· Rekrutierung
- Universitätsklinikum Köln, Klinik I - Innere MedizinVerifizierte PostleitzahlKöln, Deutschland· Rekrutierung
- Onkologisches Studienzentrum DarmstadtVerifizierte PostleitzahlDarmstadt, Germany· Rekrutierung
- Klinikum Darmstadt, Med. Klinik V, Hämatologie/OnkologieVerifizierte PostleitzahlDarmstadt, Germany· Rekrutierung
- Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. ImmunologieVerifizierte PostleitzahlDüsseldorf, Germany· Rekrutierung
- Universitätsklinik ErlangenVerifizierte PostleitzahlErlangen, Germany· Rekrutierung
- Universitätsklinikum Essen, Klinik für Hämatologie und StammzelltransplantationVerifizierte PostleitzahlEssen, Germany· Rekrutierung
Häufige Fragen
What is the main goal of this registry?
The main goal is to collect long-term health information from people with multiple myeloma who were in previous GMMG treatment studies, to understand how treatments affect them over time.
Will I receive new treatment as part of this study?
No, this is an observational study. You will continue to receive your standard medical care from your own doctors, and no new treatments are given as part of this registry.
How often will my information be collected?
Your health information will be collected every six months until your cancer progresses, and then once a year after that.
What kind of information will be collected?
Researchers will collect details about your treatments, how your health is doing, and important milestones like how long you stay well or if your condition changes.
Kann ich die Teilnahme beenden, wenn ich meine Meinung ändere?
Yes, you can choose to stop participating in the registry at any time, and this will not affect the medical care you receive.
Wie Sie mehr erfahren können
Eileen Kurre
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.